The goal of many studies around the world is to find preventive agents that may slow the progression of diabetic nephropathy in patients with type 2 diabetes mellitus at different stages of the disease, accordingly to preventing the progression of chronic kidney disease. The purpose of the work was to study the effect of complex nephroprotective therapy with the use of an inhibitor of the sodium glucose co-transporter 2 and spathogenetic therapy on metabolic parameters and the level of vasculoendothelial growth factor in blood serum of diabetic nephropathy patients at different stages of the disease. Materials and methods. 78 patients with type 2 diabetes mellitus were examined. Depending on the presence of albuminuria and glomerular filtration rate level, patients with diabetes mellitus were divided into the following groups: group I – patients with type 2 diabetes mellitus with normal glomerular filtration rate and albuminuria (n=62), group II – patients with type 2 diabetes mellitus with decreased glomerular filtration rate and albuminuria (n=16). The concentration of the vasculoendothelial growth factor was determined by enzyme-linked immunosorbent assay before and after 12 months of pathogenetic therapy. The glomerular filtration rate was calculated using the CKD EPI formula (KDIGO 2012). Patients of the first cohort received basic therapy, which included: blockers of the renin-angiotensin-aldosterone system, a coenzyme A reductase inhibitor and metformin, patients of the second cohort additionally received a sodium glucose co-transporter 2 inhibitor. Results and discussion. A decrease in vasculoendothelial growth factor levels in blood serum was found in all groups of examined patients, both under the influence of standard nephroprotective therapy, and with the use of complex treatment with an additional prescription of the sodium glucose co-transporter 2 inhibitor dapagliflozin. The highest level of response to treatment was observed in the group with the early stages of nephropathy. The therapy led to a significant improvement in the lipid spectrum of blood serum (increase of high-density lipoprotein cholesterol, decrease of total cholesterol, triglycerides and low-density lipoproteins) in all study groups. Conclusion. A decrease in serum vasculoendothelial growth factor levels against the background of an improvement in the basic clinical and laboratory parameters indicates not only an improvement kidneys function, but also a decrease in cardiovascular risk in this category of patients. The results of investigation indicate the feasibility of practical use of study vasculoendothelial growth factor serum level of diabetic nephropathy patients as an early diagnostic marker of cardiac disorders, prognosis assessment and improvement of the cardionephroprotective strategy

Keywords: diabetes mellitus, diabetic nephropathy, vasculoendothelial growth factor, chronic kidney disease, sodium glucose co-transporter 2 inhibitor

Full text: PDF (Ukr) 369K

1. Topchii T, Shcherban V. Galchinska VYu, Semenovykh P. S., Savicheva K. O. Vmist vaskuloendotelialnogo faktoru rostu v syrovattsi krovi khvorykh na tsukrovyy diabet 2 typu zalezhno vid funktsionalnogo stanu nyrok [The level of vascular endothelial growth factor in peripheral blood of type 2 diabetic patients depending on kidney functional state]. Ukrainian Journal of Nephrology and Dialysis. 2020; 3: 60-66. [Ukrainian]
2. Topchii II, Semenovykh PS, Galchinskaya VYu, Scherban’ TD, Yakimenko YuS. Stan funktsionalnoho nyrkovoho rezervu u khvorykh na tsukrovyy diabet 2-ho typu [Renal functional reserve in patients with type 2 diabetes mellitus]. Exper Clin Med. 2018; 2-3(79-80): 88-93. [Ukrainian]
3. Shen M, Gao J, Li J, Su J. Effect of ischaemic exercise training of a normal limb on angiogenesis of a pathological ischaemic limb in rabbits. Clin Sci (Lond). 2009; 117: 201-8. PMid: 19125697. https://doi.org/10.1042/CS20080212
4. Senger D.R. Vascular endothelial growth factor: much more than an angiogenesis factor. Mol Biol Cell. 2010; 21: 377-9. PMid: 20124007. PMCid: PMC2814783. https://doi.org/10.1091/mbc.e09-07-0591
5. Gavrilenko TI, Ryzhkova NA, Parkhomenko AN. Vascular endothelial growth factor in the clinic of internal diseases and its pathogenetic value. Ukrainskyi kardiolohichnyi zhurnal. 2011; 4: 87-95.
6. Shyshko ON, Mokhort TV, Konstantinova EE, Tsapaeva N.L., Mosse K.A. Rol endotelialnogo faktora rosta sosudov v patogeneze diabeticheskoy nefropatii [The Role of Vascular Endothelial Growth Factor in Pathogenesis of Diabetic Nephropathy]. Medical Journal. 2003; 1(43): 132-5. [In Russian].
7. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascularendothelial growth (VEGF) and its receptors. The FASEB Journal. 1999; 13: 10-8. https://doi.org/10.1096/fasebj.13.1.9
8. Wolf G, Chen S, Ziyadeh F.N. From the periphery of glomerular capillar wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes. 2005; 54(6): 1626-34. PMid: 15919782. https://doi.org/10.2337/diabetes.54.6.1626
9. Siemerink MJ, Augustin AJ, Schlingemann RO. Mechanisms of ocular angiogenesis and its molecular mediators. Dev Ophthalmol. 2010; 46: 4-20. PMid: 20703029. https://doi.org/10.1159/000320006
10. Docherty KF, Jhund PS, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. Eur Heart J. 2020; 41(25): 2379-92. PMid: 32221582. PMCid: PMC7327533. https://doi.org/10.1093/eurheartj/ehaa183
11. Ivanov D. Khronichne zakhvoryuvannya nyrok [Chronic kidney disease]. Liky. 2005; 35: 19-21. [Ukrainian]
12. Ivaskova EYu. Inflammatory diseases of kidneys and urinary tracts in patients with diabetes mellitus: diagnostics, treatment, prevention. Ukrainian Medical Journal. 2004; 4: 122-30.
13. Synechenko OV, Kazakov VN, Faneyrman VB. Poverkhnostnoe natyazhenye krovy y mochy pry dyabetycheskoy nefropatyy [Surface tension of blood and urine in diabetic nephropathy]. Nefrologyya. 2003; 7(1): 40-7. [IRussian]
14. Semydotskaya ZhD, Chernyakova YA, Krasovskaya EA. Partsyalnye funktsyy pochek u bolnykh dyabetycheskoy nefropatyey [Partial renal functions in patients with diabetic nephropathy]. Experymental and clinical medicine. 2002; 1: 54-6. [Russian]
15. Zhang Q, Fang W, Ma L, Wang ZD, Yang YM, Lu YQ. VEGF levels in plasma in relation to metabolic control, inflammation, and microvascular complications in type-2 diabetes: A cohort study. Medicine (Baltimore). 2018 Apr; 97(15): e0415. PMid: 29642210. PMCid: PMC5908634. https://doi.org/10.1097/MD.0000000000010415
16. Braile M, Marcella S, Cristinziano L, Galdiero MR, Modestino L, Ferrara AL, et al. VEGF-A in Cardiomyocytes and Heart Diseases. Int J Mol Sci. 2020 Jul 26; 21(15): 5294. PMid: 32722551. PMCid: PMC7432634. https://doi.org/10.3390/ijms21155294
17. Mahdy RA, Nada WM, Hadhoud KM, El-Tarhony SA. The role of vascular endothelial growth factor in the progression of diabetic vascular complications. Eye (Lond). 2010; 24: 1576-84. PMid: 20508651. https://doi.org/10.1038/eye.2010.86
18. Majumder S, Advani A. VEGF and the diabetic kidney: More than too much of a good thing. J Diabetes Complications. 2017; 31(1): 273-79. PMid: 27836681. https://doi.org/10.1016/j.jdiacomp.2016.10.020
19. Wang DQ, Miao XJ, Gao J, Zhou YH, Ji FY, Cheng XB. The 150-kDa oxygen-regulated protein (ORP150) regulates proteinuria in diabetic nephropathy via mediating VEGF. Exp Mol Pathol. 2019; 110: 104255. PMid: 31028725. https://doi.org/10.1016/j.yexmp.2019.04.014
20. Shen Y, Tong ZW, Zhou Y, Sun Y, Xie Y, Li R, et al. Inhibition of lncRNA-PAX8-AS1-N directly associated with VEGF/TGF-β1/8-OhdG enhances podocyte apoptosis in diabetic nephropathy. Eur Rev Med Pharmacol Sci. 2020; 24(12): 6864-72. https://doi.org/10.26355/eurrev_202006_21676
21. Zheng C, Huang L, Luo W, Yu W, Hu X, Guan X, et al. Inhibition of STAT3 in tubular epithelial cells prevents kidney fibrosis and nephropathy in STZ-induced diabetic mice. Cell Death Dis. 2019; 10(11): 848. PMid: 31699972. PMCid: PMC6838321. https://doi.org/10.1038/s41419-019-2085-0